CareDx (NASDAQ:CDNA) Sets New 12-Month High – Time to Buy?

15 Sep 2026, 17:44 by Tristan Rich · The Markets Daily

Shares of CareDx, Inc. (NASDAQ:CDNA – Get Free Report) hit a new 52-week high during trading on Tuesday . The company traded as high as $53.74 and last traded at $52.1560, with a volume of 151331 shares changing hands. The stock had previously closed at $52.37.

Wall Street Analysts Forecast Growth

CDNA has been the subject of a number of recent research reports. Craig Hallum raised shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a research report on Monday, August 3rd. William Blair raised shares of CareDx to a “hold” rating in a report on Thursday, July 16th. HC Wainwright reiterated a “neutral” rating and issued a $46.00 price target on shares of CareDx in a research report on Friday, July 31st. Canaccord Genuity Group assumed coverage on CareDx in a research note on Wednesday, September 2nd. They issued a “buy” rating and a $65.00 price objective for the company. Finally, Weiss Ratings raised shares of CareDx from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $51.20.

Check Out Our Latest Report on CareDx

CareDx Stock Up 1.8%

The company has a market cap of $2.76 billion, a PE ratio of 25.80 and a beta of 2.43. The firm has a 50 day simple moving average of $43.31 and a 200-day simple moving average of $28.86.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.23 by $0.14. The firm had revenue of $131.95 million during the quarter, compared to analyst estimates of $114.05 million. CareDx had a return on equity of 2.87% and a net margin of 24.23%.The business’s revenue for the quarter was up 52.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.16) EPS. As a group, equities analysts anticipate that CareDx, Inc. will post 0.47 EPS for the current year.

Insider Transactions at CareDx

In other news, Director George Bickerstaff, III sold 20,000 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $46.28, for a total transaction of $925,600.00. Following the sale, the director directly owned 134,061 shares of the company’s stock, valued at $6,204,343.08. The trade was a 12.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Walter Jr sold 39,900 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $29.24, for a total value of $1,166,676.00. Following the completion of the transaction, the chief executive officer owned 661,959 shares of the company’s stock, valued at $19,355,681.16. This trade represents a 5.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 76,000 shares of company stock worth $2,846,216. Company insiders own 2.40% of the company’s stock.

Institutional Trading of CareDx

Several institutional investors and hedge funds have recently bought and sold shares of the business. Integrated Wealth Concepts LLC acquired a new stake in shares of CareDx in the second quarter worth $29,000. Squarepoint Ops LLC lifted its position in CareDx by 759.5% during the second quarter. Squarepoint Ops LLC now owns 141,623 shares of the company’s stock valued at $4,036,000 after purchasing an additional 125,146 shares during the period. Nykredit A S acquired a new position in CareDx during the second quarter valued at $25,000. Corient Private Wealth LP purchased a new stake in CareDx in the second quarter valued at $697,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in CareDx during the 2nd quarter worth about $668,000.

About CareDx

(Get Free Report)

CareDx, Inc is a precision medicine company focused on improving outcomes for transplant patients. The company develops and commercializes diagnostic tests, monitoring solutions and digital health services designed to help clinicians assess organ health, identify potential rejection and support the long-term management of transplant recipients.